Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $6.00, with 12.05 million shares of worth about $72.3 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 100.67% during that period and on Thursday the price saw a loss of about -5.06%. Currently the company’s common shares owned by public are about 173.07M shares, out of which, 149.01M shares are available for trading.
Stock saw a price change of 1.18% in past 5 days and over the past one month there was a price change of -12.28%. Year-to-date (YTD), AUTL shares are showing a performance of -6.83% which increased to 200.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.61 but also hit the highest price of $7.45 during that period. The average intraday trading volume for Autolus Therapeutics plc ADR shares is 1.23 million. The stock is currently trading -4.19% below its 20-day simple moving average (SMA20), while that difference is up 5.59% for SMA50 and it goes to 69.96% higher than SMA200.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) currently have 173.07M outstanding shares and institutions hold larger chunk of about 55.94% of that.
The stock has a current market capitalization of $1.04B and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$0.98 in the same period. It has Quick Ratio of 8.16 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUTL, volatility over the week remained 9.27% while standing at 8.81% over the month.
Analysts are in expectations that Autolus Therapeutics plc ADR (AUTL) stock would likely to be making an EPS of -$0.25 in the current quarter, while forecast for next quarter EPS is -$0.24 and it is -$0.8 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.29 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 35.79% while it is estimated to increase by 17.19% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on November 09, 2023 offering a Buy rating for the stock and assigned a target price of $10 to it.
